Promoted Content
Promoted Content

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Labetalol

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ProvideGx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 21, 2021

            Details:

            The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9% sodium chloride injection. Deal aims support to healthcare providers, helping to meet the immediate and long-term supply needs of drugs necessary to a range of patient care interventions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amlodipine,Atorvastatin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Caduet

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: $12,000.0 million Upfront Cash: Undisclosed

            Deal Type: Merger November 16, 2020

            Details:

            Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Upjohn’s Caduet.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IBUTILIDE FUMARATE

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Premier

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 19, 2020

            Details:

            Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vericiguat

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Verquvo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bayer HealthCare

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 20, 2021

            Details:

            VERQUVO is approved for reduction of risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for HF or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Angiotensin II

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: PAION UK LTD

            Deal Size: $132.0 million Upfront Cash: $22.5 million

            Deal Type: Licensing Agreement January 12, 2021

            Details:

            La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Heparin Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fresenius Kabi AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 18, 2020

            Details:

            Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aspirin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazalore

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and a bioequivalence study data from a recently completed BE study. The submission for 81 mg dose provided for a new product strength of VAZALORE.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bempedoic Acid

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexletol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rivaroxaban

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            Janssen has submitted a supplemental New Drug Application to the FDA to expand the use of XARELTO® in patients with PAD to include reducing the risk of major thrombotic vascular events in symptomatic patients after recent lower-extremity revascularization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ephedrine

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Nevakar received approval from the FDA to market Ephedrine Sulfate Injection in a ready- to-use 50mg/10 ml single use vial presentation.